In 2025, sales are anticipated to grow by a high single-digit percentage at CER. Sanofi (SNY) confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi Faces EU Setback for Rezurock Amidst Positive Developments
- ImageneBio initiated with an Outperform at Leerink
- Sanofi: Buy Rating Affirmed on Strong Financials and Promising Growth Prospects
- Ventyx ‘unequivocally impressive data’ should spur Sanofi, says Clear Street
- Sanofi, Medidata expand partnership